<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251795</url>
  </required_header>
  <id_info>
    <org_study_id>1182.117</org_study_id>
    <nct_id>NCT02251795</nct_id>
  </id_info>
  <brief_title>Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects</brief_title>
  <official_title>Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the effect of steady-state plasma concentration of Tipranavir/ritonavir
      (TPV/r) on platelet aggregation in healthy subjects and investigate the effect of TPV/r at
      steady state plasma concentrations on other platelet functions and biomarkers of coagulation
      and fibrinolysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in the area under the curve (AUC) of platelet aggregation in response to arachidonic acid (AA)</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
    <description>calculated as the ratio of the AUC at steady state TPV plasma concentrations and the baseline AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in platelet aggregation in response to AA</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in platelet aggregation in response to collagen</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in platelet aggregation in response adenosine diphosphate (ADP)</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in closure Time (CT)</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
    <description>Platelet Function Analyzer (PFA)-100 test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinary thromboxane B2 metabolites</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in bleeding time</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in activated partial thromboplastin time (aPTT)</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in prothrombin time (PT)</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fibrinogen</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in von Willebrand antigen</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in von anti-thrombin III antigen</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in anti-thrombin III activity</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in factor II</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in factor VII</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in factor IX</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in factor X</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasminogen activity</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in alpha 2-antiplasmin</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in D-dimer</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Plasminogen Activator Inhibitor (PAI-1)</measure>
    <time_frame>Baseline, up to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration at 12 hours (Cp12h)</measure>
    <time_frame>12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from 0-12 hours (AUC0-12h)</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum measured concentration of the analyte in plasma (Tmax)</measure>
    <time_frame>up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance of the analyte in plasma (CL/F)</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (V/F)</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>pre-dose, up to 48 h after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with abnormal findings in laboratory tests</measure>
    <time_frame>up to day 61</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events</measure>
    <time_frame>up to 96 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tipranavir/Ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg Tipranavir / 200 mg Ritonavir 10 days BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir/Ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 mg Darunavir /100 mg Ritonavir 10 days BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Ritonavir 10 days BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>Tipranavir/Ritonavir</arm_group_label>
    <other_name>APTIVUS®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>Tipranavir/Ritonavir</arm_group_label>
    <arm_group_label>Darunavir/Ritonavir</arm_group_label>
    <arm_group_label>Ritonavir</arm_group_label>
    <other_name>Norvir®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <arm_group_label>Darunavir/Ritonavir</arm_group_label>
    <other_name>PREZISTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>single dose on day 2</description>
    <arm_group_label>Tipranavir/Ritonavir</arm_group_label>
    <arm_group_label>Darunavir/Ritonavir</arm_group_label>
    <arm_group_label>Ritonavir</arm_group_label>
    <other_name>Acetylsalicylic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability and willingness to give written informed consent to participate in this study
             (i.e., prior to any study-specific procedures)

          2. Age ≥18 years and ≤50 years

          3. Female subjects of child-bearing potential were eligible if:

               -  They had used a barrier contraceptive method for at least 12 weeks before
                  administration of study medication and had a negative serum pregnancy test result
                  during the screening period (Day - 35 to Day -3); or,

               -  Were abstinent for more than 12 weeks before screening and had a negative serum
                  pregnancy test result during the screening period (Day -35 to Day -3); or,

               -  Had a documented tubal ligation and had a negative serum pregnancy test result
                  during the screening period (Day -35 to Day -3)

          4. Ability to swallow capsules without difficulty

          5. Reasonable probability of completing the study

          6. Findings from medical history, physical examination and 12-lead ECG indicating subject
             was healthy and suitable for the trial in the opinion of the investigator

          7. Agreement to abstain from alcohol consumption or drugs of abuse during the study

          8. Agreement to abstain from ingestion of grapefruit, grapefruit juice, Seville oranges,
             or orange marmalade from screening period to the end of the study

          9. Negative urine drug screen for drugs of abuse

         10. Non smoker

         11. Agreement to abstain from use of tobacco products from screening period to the end of
             the study

         12. Negative HIV-1 serology by ELISA testing

         13. Negative Hepatitis B surface Antigen test (HBsAg)

         14. Negative Hepatitis C Virus antibody (anti-HCV) test by Enzyme Immunoassay

         15. Platelet count ≥125,000/mm3

         16. Hemoglobin ≥11.0 g/dL

         17. Prothrombin time ≤1.0 x upper limit of normal (ULN)

         18. Activated Partial thromboplastin time ≤1.0 x ULN

        Exclusion Criteria:

          1. Female subjects who:

               -  had a positive serum pregnancy test during the screening period (Day -35 to Day
                  -3) or during the study

               -  were breast feeding or planing to breast feed at any time from the screening
                  period through 30 days after the last dose of the study drug

               -  were not willing to use a barrier method of contraception at any time from
                  screening period through 30 days after the last dose of the study drug

               -  were taking any hormonal therapy for any reason such as birth control or
                  replacement therapy

          2. Had used any investigational agent within 30 days prior to Visit 2

          3. Blood or plasma donations (&gt;100 mL total) for research or altruistic reasons within 30
             days prior to Visit 2

          4. Had used aspirin or any non-steroidal anti-inflammatory agent (NSAID), and including
             COX-2 inhibitors, dipyridamole, clopidogrel, ticlopidine or other antiplatelet drugs
             within 14 days prior to Visit 2 or during the study

          5. Active peptic ulceration or history of peptic ulcer disease

          6. Known history of or suspected hypersensitivity to aspirin, any NSAID or any other
             component of the test drugs (Tipranavir, Darunavir, Ritonavir)

          7. Known hypersensitivity to antiretroviral drugs (marketed or experimental drug in
             clinical research studies)

          8. Active bleeding disorder or history of active bleeding disorder

          9. Active Intra cranial hemorrhage (ICH) or history of ICH

         10. Active coronary artery disease or history of coronary artery disease

         11. Alcohol abuse (more than 60 g/day)

         12. Any indication for current use of aspirin or any NSAID or indication for such use from
             Visit 2 to Visit 18

         13. Had used any over-the-counter medication within 7 days prior to Visit 2, or current
             use of any prescription drug

         14. Subjects who had an abnormal laboratory result of Grade 1 or greater, as defined by
             the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse
             Events (DAIDS), (result must have been available at least 3 days prior to Visit 2-Day
             1), except the following screening laboratory values:

               -  serum potassium, serum sodium, serum phosphate and uric acid, where central
                  laboratory reference ranges will be used to determine eligibility rather than
                  DAIDS table; or,

               -  amylase or creatinine results of Grade 1 on DAIDS table if these results are
                  considered clinically not significant by investigator; or

               -  other marginally abnormal laboratory values not considered clinically significant
                  by investigator and approved by clinical monitor

         15. History of any illness that in the opinion of the investigator might confound the
             results of the study or pose additional risks in administering aspirin, Tipranavir,
             Darunavir, or Ritonavir

         16. Hypersensitivity to sulphonamide drugs

         17. Had used proton pump inhibitors during 14 days prior to Visit 2

         18. Vitamin E intake in excess of 60 mg/day within 30 days prior to Visit 2

         19. Vitamin E supplementation in excess of 60 mg/day during the study (Vitamin E content
             of multivitamin tablets is allowed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>September 25, 2014</last_update_submitted>
  <last_update_submitted_qc>September 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

